Literature DB >> 24592492

Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study.

Gunnar Tomasson, Christine Peloquin, Aladdin Mohammad, Thorvardur J Love, Yuqing Zhang, Hyon K Choi, Peter A Merkel.   

Abstract

BACKGROUND: Involvement of large arteries is well-documented in giant-cell arteritis (GCA), but the risk for cardiovascular events is not well-understood.
OBJECTIVE: To evaluate the risks for incident myocardial infarction (MI), cerebrovascular accident (CVA), and peripheral vascular disease (PVD) in individuals with incident GCA in a general population context.
DESIGN: Observational cohort study.
SETTING: U.K. primary care database. PATIENTS: 3408 patients with incident GCA and 17 027 age- and sex-matched reference participants without baseline cardiovascular disease (MI, CVA, or PVD). MEASUREMENTS: Diagnoses of GCA, outcomes, and cardiovascular risk factors were identified from electronic medical records. One combined and 3 separate cohort analyses were conducted for the outcomes of MI, CVA, and PVD. The association of GCA with study outcomes is expressed with hazard ratios (HRs) with 95% CIs after adjustment for potential cardiovascular risk factors.
RESULTS: Among 3408 patients with GCA (73% female; mean age, 73 years), the incidence rates of MI, CVA, and PVD were 10.0, 8.0, and 4.2 events per 1000 person-years, respectively, versus 4.9, 6.3, and 2.0 events per 1000 person-years, respectively, among reference participants. The HRs were 1.70 (95% CI, 1.51 to 1.91) for the combined outcome, 2.06 (CI, 1.72 to 2.46) for MI, 1.28 (CI, 1.06 to 1.54) for CVA, and 2.13 (CI, 1.61 to 2.81) for PVD. The HRs were more pronounced in the first month after GCA diagnosis (combined HR, 4.92 [CI, 2.59 to 9.34]; HR for MI, 11.89 [CI, 2.40 to 59.00]; HR for CVA, 3.93 [CI, 1.76 to 8.79]; HR for PVD, 3.86 [CI, 0.78 to 19.17]). LIMITATION: Information on temporal arterial biopsies was not available, and there was a substantial amount of missing data on cardiovascular risk factors.
CONCLUSION: Giant-cell arteritis is associated with increased risks for MI, CVA, and PVD. PRIMARY FUNDING SOURCE: National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24592492      PMCID: PMC4381428          DOI: 10.7326/M12-3046

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

1.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

2.  Suicide and cardiovascular death after a cancer diagnosis.

Authors:  Fang Fang; Katja Fall; Murray A Mittleman; Pär Sparén; Weimin Ye; Hans-Olov Adami; Unnur Valdimarsdóttir
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

3.  Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study.

Authors:  M P Weijenberg; E J Feskens; D Kromhout
Journal:  Am J Epidemiol       Date:  1996-01-15       Impact factor: 4.897

4.  A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

Authors:  Ravi Suppiah; Andrew Judge; Rajbir Batra; Oliver Flossmann; Lorraine Harper; Peter Höglund; M Kassim Javaid; David Jayne; Chetan Mukhtyar; Kerstin Westman; John C Davis; Gary S Hoffman; W Joseph McCune; Peter A Merkel; E William St Clair; Philip Seo; Robert Spiera; John H Stone; Raashid Luqmani
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

Review 5.  Adverse effects of corticosteroids on the cardiovascular system.

Authors:  D E Sholter; P W Armstrong
Journal:  Can J Cardiol       Date:  2000-04       Impact factor: 5.223

6.  Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients.

Authors:  E Liozon; F Herrmann; K Ly; P Y Robert; V Loustaud; P Soria; E Vidal
Journal:  Am J Med       Date:  2001-08-15       Impact factor: 4.965

7.  A language of health in action: Read Codes, classifications and groupings.

Authors:  C D Stuart-Buttle; J D Read; H F Sanderson; Y M Sutton
Journal:  Proc AMIA Annu Fall Symp       Date:  1996

8.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

Authors:  Gary S Hoffman; Maria C Cid; David B Hellmann; Loic Guillevin; John H Stone; John Schousboe; Pascal Cohen; Leonard H Calabrese; Howard Dickler; Peter A Merkel; Paul Fortin; John A Flynn; Geri A Locker; Kirk A Easley; Eric Schned; Gene G Hunder; Michael C Sneller; Carol Tuggle; Howard Swanson; J Hernández-Rodríguez; Alfons Lopez-Soto; Debora Bork; Diane B Hoffman; Kenneth Kalunian; David Klashman; William S Wilke; Raymond J Scheetz; Brian F Mandell; Barri J Fessler; Gregory Kosmorsky; Richard Prayson; Raashid A Luqmani; George Nuki; Euan McRorie; Yvonne Sherrer; Shawn Baca; Bridgit Walsh; Diane Ferland; Martin Soubrier; Hyon K Choi; Wolfgang Gross; Allen M Segal; Charles Ludivico; Xavier Puechal
Journal:  Arthritis Rheum       Date:  2002-05

10.  Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis.

Authors:  J T Lie
Journal:  Arthritis Rheum       Date:  1990-08
View more
  36 in total

1.  The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study.

Authors:  J Antonio Aviña-Zubieta; Vidula M Bhole; Neda Amiri; Eric C Sayre; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2014-09-29       Impact factor: 19.103

2.  Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study.

Authors:  Max Yates; Robert Luben; Shabina Hayat; Sarah L Mackie; Richard A Watts; Kay-Tee Khaw; Nick J Wareham; Alex J MacGregor
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

3.  Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.

Authors:  Clement John Michet; Sara J Achenbach; Cynthia S Crowson; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2015-03-03       Impact factor: 5.532

4.  Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia.

Authors:  Shubhasree Banerjee; Mohammadhadi Bagheri; Veit Sandfort; Mark A Ahlman; Ashkan A Malayeri; David A Bluemke; Jianhua Yao; Peter C Grayson
Journal:  Semin Arthritis Rheum       Date:  2018-09-17       Impact factor: 5.532

Review 5.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

6.  Coronary artery stenting in acute coronary syndrome associated with giant cell arteritis.

Authors:  Lillian Armellin; Anthony Michael Sammel; Ben Ng; Kiran Sarathy; John Lambros; Taraneh Amir-Nezami; Shannon Dean Thomas; John Highton; Arvin Damodaran
Journal:  J Cardiol Cases       Date:  2017-06-27

7.  Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.

Authors:  Bryant R England; Ted R Mikuls; Fenglong Xie; Shuo Yang; Lang Chen; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

Review 8.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

Review 9.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

10.  CT analysis of the aorta in giant-cell arteritis: a case-control study.

Authors:  Pierre Emmanuel Berthod; Serge Aho-Glélé; Paul Ornetti; Olivier Chevallier; Hervé Devilliers; Frédéric Ricolfi; Bernard Bonnotte; Romaric Loffroy; Maxime Samson
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.